CURRENT AFFAIRS | 4 APRIL 2026
CLAT GK + INTERNATIONAL TRADE LAW & INTELLECTUAL PROPERTY
What Happened?
On April 2, 2026, President Trump signed an executive order imposing up to 100% tariffs on patented (branded) pharmaceutical products imported into the United States. The sweeping action followed a Section 232 Commerce Department investigation that determined certain pharmaceutical imports pose a national security risk.
Key Details of the Tariff
- 100% tariff on branded drugs from companies that have not struck pricing deals with the US government
- 20% reduced tariff for companies planning to onshore production (rising to 100% after 4 years)
- Country-specific rates: EU, Japan, Korea, Switzerland face 15%; UK faces 10%
- Implementation: 120 days for large companies, 180 days for smaller ones
Why India is Largely Unaffected
India’s pharmaceutical industry — the “Pharmacy of the World” — primarily exports generic drugs, not patented ones. Since the tariff targets only patented pharmaceutical products, India’s $27 billion generic drug export industry remains largely insulated from this action.
Legal Framework — IP & Trade Law
TRIPS Agreement (WTO): The Agreement on Trade-Related Aspects of Intellectual Property Rights sets minimum standards for IP protection across WTO member nations, including 20-year patent terms for pharmaceutical products.
Doha Declaration (2001): Affirmed that TRIPS should be interpreted to support public health and access to medicines, allowing flexibilities like compulsory licensing and parallel importation.
Section 3(d), Patents Act 1970: India’s unique anti-evergreening provision requires new forms of known substances to demonstrate significantly enhanced therapeutic efficacy to be patentable.
Novartis AG v. Union of India (2013): The Supreme Court upheld Section 3(d), rejecting Novartis’s patent for the beta crystalline form of imatinib mesylate (Gleevec), a landmark ruling protecting generic drug access.
CLAT Exam Angle
This topic is a CLAT goldmine combining trade law, IP, and current affairs:
- WTO & Trade Law: Most Favoured Nation (MFN) principle, National Treatment, Section 232 tariffs vs WTO compliance
- Intellectual Property: TRIPS flexibilities, compulsory licensing (India’s first CL — Natco v. Bayer, 2012 for Nexavar), parallel importation
- Indian Patent Law: Section 3(d) anti-evergreening, Novartis v. UoI (2013), process vs product patents
- Public Health: Doha Declaration, access to medicines in developing countries, India’s role as generic drug supplier
Key Facts at a Glance
| Tariff Rate | Up to 100% on patented pharma drugs |
| Legal Basis | Section 232 (National Security) |
| Signed | April 2, 2026 (Executive Order) |
| India Impact | Limited — India exports generics, not patented drugs |
| Key Indian Law | Patents Act 1970, Section 3(d) |
| Landmark Case | Novartis v. UoI (2013) |
| WTO Framework | TRIPS Agreement + Doha Declaration |
| First Indian CL | Natco Pharma v. Bayer (2012) — Nexavar |
Memory Aid for CLAT
Remember “TRIPS” for WTO IP Framework:
- T — Twenty years patent protection minimum
- R — Rights include patents, copyrights, trademarks, GIs
- I — India’s Section 3(d) — anti-evergreening safeguard
- P — Public health flexibilities (Doha Declaration)
- S — Special provisions for developing countries (transition periods, CL)
Novartis Case Mnemonic — “GLEEVEC”: Generic access, Legal battle, Efficacy requirement (Sec 3(d)), Evergreening blocked, Verdict by SC, Essential medicines protected, Constitutional validity upheld
Practice Quiz
Practice Quiz — 10 CLAT-Style Questions
Click an option to reveal the answer and explanation.
